IMMUCELL CORP. DL-10
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotaviru… Read more
IMMUCELL CORP. DL-10 (IUL) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, IMMUCELL CORP. DL-10 (IUL) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IMMUCELL CORP. DL-10 - Net Assets Trend (None–None)
This chart illustrates how IMMUCELL CORP. DL-10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IMMUCELL CORP. DL-10 (None–None)
The table below shows the annual net assets of IMMUCELL CORP. DL-10 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to IMMUCELL CORP. DL-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
IMMUCELL CORP. DL-10 Competitors by Market Cap
The table below lists competitors of IMMUCELL CORP. DL-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coreline Soft, Co., Ltd.
KQ:384470
|
$33.29 Million |
|
Scottie Resources Corp
OTCQB:SCTSF
|
$33.31 Million |
|
Swelect Energy Systems Limited
NSE:SWELECTES
|
$33.33 Million |
|
Sunty Development Co Ltd
TW:3266
|
$33.34 Million |
|
Shine-On BioMedical Co.,Ltd.
TWO:6926
|
$33.28 Million |
|
Hsin Ba Ba Corp
TW:9906
|
$33.28 Million |
|
Gala Precision Engineering
NSE:GALAPREC
|
$33.28 Million |
|
Boab Metals Limited
PINK:PMYLF
|
$33.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IMMUCELL CORP. DL-10's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares IMMUCELL CORP. DL-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently IMMUCELL CORP. DL-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares IMMUCELL CORP. DL-10's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IMMUCELL CORP. DL-10 (IUL) | €- | N/A | N/A | $33.28 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |